Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11891439-B2
Publication Date
2024-02-06
Expiration Date
Abstract
The invention provides CCL14 antibodies.
Core Innovation
The disclosure provides monoclonal antibodies and antigen-binding fragments that specifically bind human CCL14, including antibodies defined by heavy- and light-chain variable-region CDRs and framework regions exhibiting at least 90% sequence similarity. It also describes framework variants, antibody pairs, diagnostic kits, and CCL14 epitopes. The antibodies are utilized in CCL14 immunoassays in sandwich and competitive formats, including lateral-flow test devices and analyzer-based systems.
The disclosure describes epitope mapping assigning distinct CCL14 epitopes to antibody clones and reports sandwich-complex formation across tested antibody pairs, calibration curves, and assay configurations. The available content identifies in-vitro diagnostic and therapeutic applications involving CCL14. The background problem addressed by the invention or underlying limitation motivating the disclosure is not explicitly described in the patent content.
Claims Coverage
The claims identify three independent claims covering three inventive features directed to CCL14-binding antibodies or fragments, framework sequence similarity, and epitope binding.
CCL14-binding antibody with specified CDRs
Independent claim 1 covers a monoclonal antibody or antigen-binding fragment that specifically binds human CCL14 and comprises heavy-chain variable-region CDRs from SEQ ID NO: 7 and light-chain variable-region CDRs from SEQ ID NO: 8.
Antibody with framework sequence similarity
Independent claim 15 covers a monoclonal antibody or antigen-binding fragment comprising the heavy- and light-chain CDRs from SEQ ID NOs: 7 and 8 and at least 90% sequence similarity in the respective heavy- and light-chain framework sequences.
Antibody binding human CCL14 or a specified epitope
Independent claim 18 covers an antibody or specified antibody fragment with heavy- and light-chain variable-region sequences from SEQ ID NOs: 7 and 8 that specifically binds human CCL14 or binds an epitope comprising all or part of SEQ ID NO: 23.
The independent claims cover CCL14-binding antibodies and fragments defined by their variable-region CDRs or sequences, framework sequence similarity, and binding to a specified CCL14 epitope.
Stated Advantages
Not explicitly described in patent.
Documented Applications
CCL14 immunoassays and diagnostic kits configured to detect the presence or amount of human CCL14 in a biological sample, including sandwich, competitive, lateral-flow, and analyzer-based assay formats.
Diagnostic and therapeutic applications involving CCL14.
Interested in licensing this patent?